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Increasingly, patients with unhealthy alcohol and other drug use are being seen in primary care and other non-specialty
addiction settings. Primary care providers are well positioned to screen, assess, and treat patients with alcohol and other
drug use because this use, and substance use disorders, may contribute to a host of medical and mental health harms.
We sought to identify and examine important recent advances in addiction medicine in the medical literature that have
implications for the care of patients in primary care or other generalist settings. To accomplish this aim, we selected
articles in the field of addiction medicine, critically appraised and summarized the manuscripts, and highlighted their
implications for generalist practice. During an initial review, we identified articles through an electronic Medline search
(limited to human studies and in English) using search terms for alcohol and other drugs of abuse published from January
2010 to January 2012. After this initial review, we searched for other literature in web-based or journal resources
for potential articles of interest. From the list of articles identified in these initial reviews, each of the six authors
independently selected articles for more intensive review and identified the ones they found to have a potential
impact on generalist practice. The identified articles were then ranked by the number of authors who selected
each article. Through a consensus process over 4 meetings, the authors reached agreement on the articles with
implications for practice for generalist clinicians that warranted inclusion for discussion. The authors then grouped
the articles into five categories: 1) screening and brief interventions in outpatient settings, 2) identification
and management of substance use among inpatients, 3) medical complications of substance use, 4) use of
pharmacotherapy for addiction treatment in primary care and its complications, and 5) integration of addiction
treatment and medical care. The authors discuss each selected articles’ merits, limitations, conclusions, and
implication to advancing addiction screening, assessment, and treatment of addiction in generalist physician
practice environments.
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Increasingly, patients with unhealthy alcohol and other
drug (AOD) use are being seen in primary care and other
nonspecialty addiction settings. Primary care providers are
well-positioned to screen, assess, and treat patients with
AOD use because these conditions may contribute to a
host of medical and mental health harms. An ever-present
concern is the length of time that it takes to translate* Correspondence: gordona@medschool.pitt.edu
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stated.evidence-based AOD screening, assessment, and treatment
approaches into real-world settings. Several publications fo-
cusing on the integration of AOD care into primary care
settings have sought to disseminate the latest evidence to
generalist clinicians, including the 2012 Update in Addic-
tion Medicine for the Generalist published in this journal
[1-6]. In order to provide a recent update, the authors pre-
sented a 2013 Addiction Update for the Generalist at the
annual meeting of the Society of General Internal Medicine
(SGIM) in the spring of 2013. The following paper de-
scribes the literature reviewed during this presentation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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advances in addiction medicine in the medical literature
that have implications for the care of patients in primary
care or other generalist settings. To accomplish this
aim, we selected articles in the field of addiction medi-
cine, critically appraised and summarized the manuscripts,
and highlighted their implications for generalist practice,
employing methodology used in prior updates [3-6].
During an initial review, we identified articles through an
electronic Medline search (limited to human studies and in
English) using search terms for alcohol and other drugs of
abuse published from January 2010 to January 2012. After
this initial review, we searched for other literature in web-
based or journal resources (e.g., Alcohol, Other Drugs,
and Health: Current Evidence [www.bu.edu/aodhealth], the
American College of Physicians (ACP) Journal Club, tables
of contents of relevant journals) for potential articles of
interest. From the list of articles identified in these initial re-
views, each of the six authors independently selected arti-
cles for more intensive review and identified the ones they
found to have a potential impact on generalist practice. The
identified articles were then ranked by the number of au-
thors who selected each article.
Through a consensus process in monthly meetings over
the course of five months, the authors reached agreement
on the articles with implications for practice for generalist
clinicians that warranted inclusion. The authors then
grouped the articles into five categories: 1) screening and
brief intervention in outpatient settings, 2) identification
and management of substance use among inpatients, 3)
medical complications of substance use, 4) use of pharma-
cotherapy for addiction treatment in primary care and its
complications, and 5) integration of addiction treatment
and medical care.
Screening and brief intervention in outpatient settings
Screening and brief intervention (SBI) is an evidence-based
practice model for identifying and addressing unhealthy al-
cohol use in general health-care settings, and SBI for sub-
stance use carries a Grade B recommendation from the
United States Preventive Services Task Force (USPSTF) [1].
The SBI approach typically begins with opportunistic
screening in general health care settings with a goal of iden-
tifying patients with unhealthy substance use who are not
seeking substance abuse treatment. Those patients who
screen positive are followed up with a brief counseling
intervention, which is usually delivered during the same
medical visit. Screening, brief intervention, and referral to
treatment (SBIRT) programs addressing both drug and al-
cohol use are widely promoted by health authorities in the
US and are supported by insurance billing codes. Nonethe-
less, SBI is rarely integrated into regular primary care prac-
tice [7,8].While there is ample evidence to support the use
of SBI for unhealthy or hazardous alcohol use, concernshave been raised about the lack of evidence for SBI for pa-
tients with alcohol dependence [9] and for addressing other
drug use disorders [7-10].
Evidence supporting alcohol brief interventions in adult
primary care settings has largely been derived from efficacy
trials [11-14], and important questions remain about how
SBI can be implemented within regular medical care and
the ‘dose’ of intervention needed for it to be effective. Alco-
hol SBI research is now moving toward gathering more
practice-based evidence, with studies integrating SBI into
regular care processes without reliance on research staff.
This has exposed the considerable barriers to SBI imple-
mentation [4-6,15], including limited time to perform BI
and physician knowledge in this area [16-21].
How effective is alcohol screening and brief intervention
when implemented in usual care?
Kaner E, et al. [15], D’Onofrio G, et al. [22] Kaner and col-
leagues [15] undertook a pragmatic trial of three brief inter-
vention strategies in primary care settings as part of the
large multi-center Screening and Intervention Programme
for Sensible drinking (SIPS) trial conducted in the UK. Over
3500 patients across 29 primary care practices participated
in this cluster randomized trial. Practices were assigned to
one of three interventions of increasing levels of intensity:
simple feedback plus a patient information leaflet (provided
for all interventions); a five-minute structured brief inter-
vention delivered by practice staff; or a brief intervention
followed by a 20-minute motivational interviewing session
delivered at a follow-up visit by an alcohol counselor. The
primary outcome was drinking status as measured by the
Alcohol Use Disorders Identification Test (AUDIT).
Hazardous and harmful drinking decreased in all treatment
conditions at six and 12 months, but the odds of having a
negative AUDIT score did not differ significantly between
those who received the pamphlet versus the brief intervention
(OR=0.85) or motivational interviewing (OR=0.78). Readi-
ness to change appeared to have a dose-related response to
the amount of counseling received, but no differences were
observed in alcohol-related problems or health-related quality
of life. With no treatment-as-usual group, the investigators
were unable to evaluate whether the observed changes in
drinking outcomes could be attributed to effectiveness of the
interventions versus regression toward the mean.
This pragmatic trial illustrated some of the implementa-
tion challenges to integrating SBI into primary care settings.
Many sites were unable to recruit the initial target of 31 pa-
tients per practice. Follow-up rates for the brief lifestyle
counseling intervention were relatively low, with just 57%
of eligible patients returning for the dedicated counseling
visit. The authors concluded that, based on results from this
trial, there may be no additional benefit of counseling inter-
ventions over simple feedback and written information in
addressing unhealthy alcohol use in primary care.
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alcohol SBI when delivered by medical staff in the emer-
gency department (ED). Prior research on the impact of
brief interventions for unhealthy alcohol use in ED set-
tings has been inconclusive, with a recent meta-analysis
showing no significant impact on alcohol consumption
but a 50% reduction in alcohol-related injury [23]. This
single-site study by D’Onofrio and colleagues [22] ex-
amined the effect of a brief intervention conducted by
the medical provider (median duration = 7 minutes),
with or without a booster call, compared to standard
care. Eligibility was restricted to patients with hazardous
and harmful drinking (representing 2.8% of all patients
screened) and excluded individuals with alcohol depend-
ence. Among the 889 participants, reductions were seen
in the mean number of drinks in the past seven days and
mean number of binge episodes in the past 28 days at six
and 12 months in all treatment conditions. Reduction in
drinking was significantly greater in those who received
the brief intervention compared with standard care, but
there was no additional benefit from the booster call.
Rates of driving after drinking were significantly reduced
for the brief intervention groups compared with standard
care. This study supports the effectiveness of a single brief
intervention in the ED, using existing ED staff, for individ-
uals with hazardous or harmful drinking.
How feasible and effective is implementation of SBI in
real-world primary care settings?
Van Beurden I, et al. [24], Hilbink M, et al. [25] In a ran-
domized clinical trial of community-based practices, SBI
reduced alcohol-related problems in people with un-
healthy alcohol consumption who did not meet criteria for
alcohol dependence [26]. While a number of studies have
examined strategies to engage providers in addressing haz-
ardous alcohol consumption, there are still relatively few
examples of practical implementation trials conducted in
routine primary care practice.
Two articles reported findings from a large cluster ran-
domized controlled trial of a tailored, multi-component
intervention for addressing hazardous drinking. Seventy-
seven practices, including 119 general practitioners and
6318 patients, participated in the study. Hazardous drink-
ing was addressed at three levels: the implementation
strategy included professional-directed interventions, such
as guideline distribution, reminder desk cards, and educa-
tional training sessions for the care teams; organization-di-
rected interventions, which included the proportion of
patients with hazardous/harmful use and dependence,
facilitation of referrals to local addiction programs, and
outreach to the practice by a trained facilitator; and
patient-directed interventions, e.g., waiting room posters
and patient information letters including personalized
feedback on their alcohol use. Intervention practices wererandomized to receive all three levels of the intervention.
The control practices only received patient-directed infor-
mation letters. The main outcomes were receipt of screen-
ing and advice at 12 months measured at the practice level
and the proportion of hazardous drinking patients who re-
ported reduced use to low risk levels at two years mea-
sured at the individual level.
Participating practices were primarily small clinics having
one (48%) or two (35%) general practitioners. Implementa-
tion of SBI was thwarted by low recruitment and staff mo-
tivation (e.g., 13 general practitioners missed all trainings,
only half of the intervention practices met the minimum
requirements for participation). For the practice-level out-
comes, there were no significant improvements in screening
or advice-giving at 12 months. For the individual-level out-
comes, 41.6% of patients with hazardous and harmful drink-
ing reduced their consumption to low-risk levels. However,
more (47%) individuals in the control group reduced alco-
hol use than in the intervention group (36%), which was an
effect in the opposite direction than hypothesized.
Large-scale implementation of SBI for alcohol in
primary care is challenging, and programs that fail to
adequately address provider and patient attitudes, system-
and practice-level barriers, education, and provider in-
centives for providing SBI services may not confer the
benefits found in smaller or more intensive efficacy stud-
ies [12]. Unfortunately, these reports by Van Beurden
and Hilbink do not provide analyses of the individual
program components, which could have provided im-
portant guidance for future programs. While the find-
ings from this study should be considered alongside
examples of successful SBI implementation [17,27], more
research focused on determining the most effective strat-
egies for successfully integrating, scaling up, and creating
sustainable evidence-based SBI for alcohol use in pri-
mary care is clearly needed.
What is the efficacy of screening and brief intervention
for drugs other than alcohol?
Humeniuk R, et al. [28] In contrast to the field of alcohol
SBI, where research is moving from efficacy to effective-
ness trials, there have been few rigorous clinical trials
examining the efficacy of SBI for illicit drugs [10]. A study
by Humeniuk and colleagues addressed this important re-
search question in a randomized clinical trial examining
the efficacy of a single brief intervention linked to the Al-
cohol, Smoking and Substance Involvement Screening
Test (ASSIST) in primary care settings. The ASSIST is a
screening and assessment instrument developed by the
World Health Organization (WHO) that screens for life-
time and current substance use and queries a range of
substance use-related problems, generating a substance-
specific risk score that categorizes use as low, moderate,
or high risk [29].
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of at least one illicit drug were enrolled from diverse out-
patient care sites (including community health centers,
sexually transmitted disease clinics, and dental clinics) in
four countries (Australia, Brazil, India, and the US).
Screening and brief interventions were conducted on-site
by research staff, and the intervention focused on the sub-
stance of greatest concern (i.e., cannabis, cocaine, or opi-
oids). The primary outcomes were change in global and
substance-specific ASSIST scores assessed at three
months. Based on an intention-to-treat analysis, the
pooled results for all study sites showed a significant re-
duction in the global substance use score: mean effect size
was 18% in the brief-intervention group versus 11% in the
control condition (p < 0.001). Decreases were seen in can-
nabis and stimulant use scores in some countries, and opi-
oid use scores decreased in India (the only country with
sufficient prevalence to assess this substance class). No
significant effect was seen at the US sites on either global
substance ASSIST scores or on cannabis or stimulant
scores. The authors speculated that lengthier consent pro-
cedures used in the US diminished the treatment effect of
brief intervention in these sites. Important limitations of
this study were the use of research staff to conduct all
screening and interventions and the use of change in AS-
SIST score, which is of unknown clinical significance, as
the primary outcome. Overall, this study indicates that SBI
may be effective for some drugs and in some settings, but
more research is needed on the efficacy of SBI for drugs
other than alcohol.Implications for practice
Primary care providers should perform SBI for un-
healthy alcohol use as recommended by the USPSTF,
and expanding these services to ED settings should be
considered. Introducing SBI into busy general health
care settings continues to pose a challenge, and more
research is needed to guide implementation of best
practices. An example of an alternative implementation
approach is a study in adolescent primary care clinics
that used computer-delivered SBI in the waiting room,
where it was well-accepted, doubled rates of BI counsel-
ing by primary care providers, and significantly reduced
alcohol use [30]. The studies reviewed here also suggest
that more may not be better when it comes to the dose of
brief intervention, and that it can be difficult to motivate
patients to return to clinic for additional counseling, even
when it is offered in the same location where they receive
primary care. Finally, while there may be benefits to com-
bining AOD screening and interventions (and, in many
populations, this may be a clinically-sound approach), the
efficacy of SBI for reducing unhealthy illicit drug use re-
mains in question.Identification and management of substance use
among inpatients
Among patients with alcohol and/or drug dependence,
medical complications and comorbidity are common
[31], and substance use disorders have been shown to
lead to high rates of ED visits and inpatient hospitaliza-
tions [32,33]. Substance use may negatively impact hos-
pital stay, undermine discharge planning, and lead to
readmissions and increased health care use [34]. At the
same time, hospitalization also represents a teachable
moment and an opportunity to perform interventions
and initiate treatment.What is the influence of a substance use disorder
diagnosis on acute care hospital utilization?
Walley AY, et al. [35] This observational cohort study
examined the rate (total number of ED visits and re-
hospitalizations per subject) and risk (proportion of sub-
jects with an ED visit or rehospitalization) of acute care
hospital utilization within 30 days of hospital discharge. It
is a secondary data analysis of Project RED (Re-Engineered
Discharge), a randomized trial of reengineered discharge
services for adults admitted to Boston Medical Center from
January 2006 through October 2007 [36,37]. The outcomes
were determined by medical record review for health-care
utilization occurring at Boston Medical Center (all subjects)
and by phone interview for utilization occurring elsewhere
(86% of subjects were contacted). Substance use disorders
were identified by discharge diagnostic codes from the
International Classification of Diseases, 9th Revision (ICD-
9), and subjects were classified as having an alcohol use dis-
order diagnosis, a drug use disorder diagnosis, or both.
At discharge, 17% of subjects had an identified substance
use disorder diagnosis. Subjects with substance use disor-
ders had higher rates of recurrent acute-care hospital
utilization than subjects without (0.63 versus 0.32 events
per subject at 30 days, p < 0.01) and an increased risk of
any recurrent acute care hospital utilization (33% versus
22% at 30 days, p < 0.05). Adjusting for known factors asso-
ciated with readmission (age, sex, having a primary care
physician, depression symptoms, homelessness in the past
three months, employment and insurance status, Charlson
Comorbidity Index score, and project RED group assign-
ment), the incident rate ratio at 30 days was 1.49 (95% con-
fidence interval [CI], 1.12-1.98) for subjects with substance
use disorders compared to those without. The odds ratio
for the risk of reutilization was 1.38 (95% CI, 0.88-2.17) for
subjects with substance use disorders compared with those
without, but this increase was not statistically significant. In
a secondary analysis, higher utilization was attributable to
those with drug use disorder diagnoses or a combination of
drug and alcohol use disorder diagnoses, but not to those
exclusively with alcohol use disorder diagnoses.
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are common among medical inpatients and warrant con-
sideration by policy makers, insurance companies, and
hospitals in developing new strategies intended to reduce
rehospitalization among hospital inpatients.
Can screening for unhealthy alcohol use identify patients
at risk for increased postoperative health-care utilization?
Rubinsky A, et al. [38] A previous study showed that the
AUDIT-C (an alcohol screening test comprised of the
three consumption questions from the AUDIT) can help
identify patients at risk for postoperative complications
[39]. This cohort study was conducted among 5171 male
Veterans Health Administration (VA) patients of at least
21years of age who completed the AUDIT-C on mailed
surveys from October 1, 2003, to September 30, 2006,
and who were hospitalized in the subsequent year for at
least one day for nonemergent noncardiac major opera-
tions. The study assessed whether the AUDIT-C could
help identify patients at risk for increased postoperative
health-care use. The outcomes were postoperative health-
care use (hospital length of stay, number of days spent in
the intensive care unit [ICU], return to the operating room
in the 30 days after surgery, hospital readmission in the 30
days post-discharge) evaluated across four AUDIT-C risk
groups: nondrinkers (score of 0) and low-risk (1 to 4), at-
risk (5 to 8), and high-risk (9 to 12) drinkers.
More than half of the study sample reported drinking in
the past year; 1853 (36%) were low-risk drinkers, 649
(13%) were at-risk drinkers, and 230 (4%) were high-risk
drinkers. Compared with the low-risk group, high-risk
drinkers had longer postoperative hospital lengths of stay
(5.8 days [95%, 5.0-6.7] versus 5.0 days [95% CI, 4.7-5.3]),
more ICU days (4.5 [95% CI, 3.2-5.8] versus 2.8 [95% CI,
2.6-3.1]), an increased probability of return to the operat-
ing room in the 30 days after surgery (10% [95% CI, 6-
13%] versus 5% [95% CI, 4-6%]), but no increased hospital
readmission within 30 days post-discharge (7% [95% CI, 4-
11%] versus 6% [95% CI, 5-7%]). Analyses were adjusted
for age at the time of surgery, race, marital status, service-
connected disability, past-year smoking status, surgical
procedure category based on Current Procedural Termin-
ology codes (i.e., cardiovascular or thoracic, musculoskel-
etal, gastrointestinal, genitourinary, or other—a proxy
measure of surgical complexity), and days from alcohol
screening to surgery. At-risk drinkers did not differ signifi-
cantly from low-risk drinkers on any measure of postoper-
ative health-care use.
This study demonstrates that a simple screening test
for alcohol use can help identify patients at risk for post-
operative health care use. Further research is needed to
elucidate the contributors of increased risk in this popu-
lation and to develop effective interventions to mitigate
this risk.How can substance use be addressed at the hospital to
increase continuity of care and transition to addiction
treatment?
Pecoraro A, et al. [40] Addressing substance use disorders
among inpatients can decrease acute-care utilization and
may lead to engaging patients in addiction care. The
authors completed a retrospective data evaluation of a
pilot program (Project Engage) which was conducted at
Wilmington Hospital in Delaware. Its purpose was to
identify and facilitate entry of medical and surgical inpa-
tients to substance use disorder treatment after discharge.
The program was designed to provide bedside assistance
for the clinical team to address substance use disorders.
Patients with substance use disorders were identified by
clinicians (based on clinical judgment, without systematic
screening). Patients received motivational interviewing
and facilitated referral to treatment by a patient engage-
ment specialist. Patient engagement specialists were in
stable recovery from alcohol and/or drugs for at least two
years. They provided one to two motivational-interviewing
sessions while the patients were at the hospital to enhance
motivation to attend substance use treatment; discussed
potential treatment programs when patients were willing
to consider substance use treatment; determined whether
programs had openings; investigated whether and how
treatment could be funded; made appointments; and ad-
dressed potential barriers to treatment (e.g., homelessness,
clothing, transportation). They called patients within 48
hours of the planned admission or appointment. The out-
comes were self-reported rates of substance-use treatment
initiation among all patients. Of the 415 patients who par-
ticipated in Project Engage, 180 (43%) were admitted to a
substance-use treatment program. Most (57%) attended
outpatient addiction facilities, while 29% were admitted to
residential treatment.
These results are promising and suggest that the identi-
fication and facilitation of addiction treatment entry are
worthwhile. Nevertheless, given the nature of the study
and its design, there is a need for additional studies focus-
ing on continuity of care and transition to addiction
treatment.
What is the evidence for smoking cessation interventions
among inpatients?
Rigotti N, et al. [41] Numerous studies have assessed the
impact of conducting smoking cessation interventions
while patients are hospitalized. In this Cochrane system-
atic review, Rigotti and colleagues determined the effect-
iveness of interventions for smoking cessation initiated at
the hospital for patients who were current smokers or
recent quitters. They conducted a systematic review of
randomized and quasi-randomized trials of behavioral,
pharmacological, or multicomponent interventions started
at the hospital to help patients stop smoking.
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cording to intensity and presence of post-discharge sup-
portive contacts: 1) single contact in hospital lasting 15
minutes or less with no follow-up support, 2) one or
more contacts in hospital lasting a total of more than 15
minutes with no follow-up support, 3) any hospital con-
tact plus follow-up for up to one month, and 4) any hos-
pital contact plus follow-up over one month.
Counseling interventions (n = 25) that began during
the hospital stay and continued with supportive con-
tacts for at least one month after discharge increased
smoking cessation rates following discharge (risk ratio
[RR], 1.37; 95% CI, 1.27-1.48) (25 trials). Interventions
of lower intensity did not show significant increased
smoking cessation rates. Adding nicotine replacement
therapy to an intensive counseling intervention in-
creased smoking cessation rates compared with coun-
seling alone (RR 1.54; 95% CI 1.34-1.79) (six trials).
Adding varenicline (two trials) or bupropion (three tri-
als) to intensive counseling had no significant effect.
These results indicate that counseling interventions
for smoking cessation delivered in a hospital are effect-
ive as long as patients are also offered supportive con-
tacts post-discharge, and that nicotine replacement
therapy is likely to increase the efficacy of counseling
delivered at the hospital.
Is hospitalization an acceptable moment to perform brief
intervention for unhealthy alcohol use?
Broyles LM, et al. [42] The implementation of SBIRT is
encouraged in inpatient settings but, questions remain
with regard to its acceptability and efficacy. Broyles and
colleagues investigated whether nurse-delivered brief
intervention would be acceptable to inpatients in a cross-
sectional survey of 370 hospitalized medical-surgical pa-
tients at a large university-affiliated VA medical center.
Factors potentially associated with acceptability were
assessed. Patient acceptability was high; most patients
agreed/strongly agreed that it would be okay to be asked
about their alcohol use or to discuss it with a nurse (95%),
and agreed/strongly agreed that if drinking were impacting
their health, a nurse should advise them to cut down
(94%) or quit (84%) drinking. Patients were less accepting
of the offer to be referred to an alcohol treatment program
(78% of patients agreed or strongly agreed that it would be
okay). Patients were more accepting of SBIRT if they felt
able to determine their alcohol risk level, believed that it
would be possible to reduce their alcohol-related health
risks, and expressed some degree of concern about their
own use of alcohol. Approximately 20% of patients re-
ported some degree of personal discomfort with alcohol-
related discussions.
These results indicate that patients, even when report-
ing some degree of discomfort with the topic, find itacceptable for nurses to talk to them about alcohol while
they are at the hospital, indicating that SBIRT imple-
mentation in hospital may be feasible. Factors associated
with SBIRT acceptability in this study tended to suggest
that those who are more likely to be in need of an inter-
vention are those who are also less likely to accept it.
Furthermore, these results should be considered within
the context of the conflicting evidence with respect to
alcohol SBIRT efficacy among inpatients [43,44].
Implications for practice
In summary, there is growing evidence of the importance
of substance use as a major determinant of health among
inpatients; it can impact readmission, length of stay, and
postoperative outcomes. Available screening tools for un-
healthy alcohol use can be used to predict postoperative
outcomes and hospital stay. Hospitalization and hospital
discharge may represent an opportunity to prevent nega-
tive consequences of substance use. Further studies fo-
cused on coordinated and integrated interventions and
treatments for inpatients with substance use are needed.
Medical complications of substance use
The burden of medical complications of substance use on
the population increases with greater use. Here, we focus
on the complications of three of the most commonly used
substances: marijuana, alcohol, and opioid analgesics.
The past decade has seen loosening of marijuana regula-
tion at the state level, including provisions allowing med-
ical marijuana use in 18 states and recreational use in
Colorado and Washington, but questions remain about
the safety of marijuana use. Alcohol use is widespread, but
most studies of alcohol-related complications have evalu-
ated the effects of moderate to heavy alcohol use, and less
is known about the impact of light to moderate alcohol
consumption, which is more common. In the past decade,
as prescription of opioid analgesics has markedly increased.
the US has seen substantial increases in non-medical use
of opioid medications, the number of diagnosis of opioid
use disorders, and overdose deaths. We report on two ef-
forts to reverse this: prescription monitoring programs and
abuse-deterrent formulations.
Does long-term marijuana use cause lung disease?
Pletcher MJ, et al. [45] It is well-established that smoking
tobacco causes lung disease, but data about the impact of
marijuana use on pulmonary function are limited. This
20-year prospective study of 5115 adults evaluated the
long- and short-term effects of smoking marijuana, to-
bacco, or both on pulmonary function tests. They found
that while tobacco use was associated with linear de-
creases in forced expiratory volume in the first second
(FEV1) and in forced vital capacity (FVC), consistent with
previous studies, marijuana use had no adverse effect on
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“joint-years” during their lifetime (e.g., an average of one
joint per day for 10 years, or two joints per day for five
years). Light marijuana use was associated with increases
in both FEV1 and FVC, but there was a nonsignificant
trend towards decreased FEV1 with higher levels of use, in-
dicating a possible negative effect of marijuana use on pul-
monary function at high levels of intake.
Does marijuana use increase the risk of motor
vehicle accidents?
Asbridge M, et al. [46] Driving under the influence of
marijuana has increased in prevalence, but the evidence
about collision risk is inconsistent. This systematic review
and meta-analysis of observational epidemiologic studies
evaluated the impact of recent marijuana use on the risk
of collision resulting in serious or fatal injury. Recent
marijuana use was determined by either whole blood toxi-
cology or self-reported use within three hours preceding
the collision. In a pooled analysis of 49,411 participants in
nine studies, the risk of collision nearly doubled after
using marijuana without other substances (OR, 1.92 for
any collision [95% CI, 1.35, 2.73], p <0.001; and 2.10 for
fatal collision [95% CI, 1.31, 3.36), p = 0.002).
Does light alcohol use increase the risk of cancer?
Bagnardi V, et al. [47] Moderate and high alcohol con-
sumption increases one’s risk of developing colorectal,
breast, laryngeal, liver, esophageal, and oropharyngeal can-
cer, but little is known about the impact of light alcohol
consumption. This study was a meta-analysis of case–con-
trol or cohort studies that reported cancer outcomes
among individuals with alcohol intake of up to one drink
per day (“light drinkers”), compared with individuals with
no alcohol consumption. They identified 222 studies with
approximately 92,000 light drinkers with cancer and found
that light drinking was associated with cancer of the oro-
pharynx (RR, 1.17 [95% CI, 1.06-2.29), female breast (RR,
1.05 [95% CI, 1.02-1.08), and squamous cell carcinoma of
the esophagus (RR, 1.30 [95% CI, 1.09-1.56). They found
no significant associations of light drinking with colorec-
tal, laryngeal, or liver cancer. These findings highlight that
even light alcohol use carries risk.
Is light alcohol intake protective against heart disease?
Roerecke M, et al. [48] Results of prior studies indicate
that low to moderate alcohol consumption might be cardi-
oprotective, but the evidence is limited. In particular, the
dose–response relationship is unknown and may differ in
women and men. This study was a systematic review and
meta-analysis of case–control or cohort studies that re-
ported ischemic heart disease morbidity and mortality, by
average alcohol consumption, using lifetime abstainers as
the reference group. The authors identified 44 studies,with approximately 960,000 participants. Even with this
large amount of data, results were intriguing but not con-
clusive because of substantial heterogeneity and confound-
ing. They found J-shaped curves for both women and
men, indicating that low alcohol use was associated with
lower reduced ischemic heart disease mortality, but higher
alcohol use was associated with greater ischemic heart dis-
ease mortality. For women, up to one drink per day was
cardioprotective (RR, 0.84 [95% CI, 0.74-0.96]). For men,
three drinks per day was cardioprotective (RR, 0.78 [95%
CI, 0.63-0.97]), but surprisingly, one or two drinks was
not. This study gives further support to the conclusion
that light alcohol may be cardioprotective, but effects dif-
fer by sex and further research is needed.
Are prescription monitoring programs effective at
reducing opioid analgesic abuse or overdose?
Reifler L, et al. [49] Over the past decade, states through-
out the US have responded to increases in prescription
drug abuse and overdose by implementing prescription
monitoring programs (PMPs), which variably allow pre-
scribers to access state-run databases of pharmacy fills for
controlled substances. Goals of PMPs are to help pre-
scribers identify undisclosed sources of controlled sub-
stances, identify patients who are abusing or diverting
their prescribed opioids, and ultimately, to reduce the
prevalence of opioid abuse and overdose. To date, only
limited equivocal data exist about the effectiveness of
PMPs in reducing prescription drug abuse or overdose.
This ecologic study of states with and without PMPs is
one of the first national studies of PMP effectiveness. On a
quarterly basis from 2003–2009, states were classified as
either having a PMP or not, and then by two measures of
opioid analgesic abuse: intentional exposures reported to
poison centers and use to get high among individuals en-
tering drug treatment. They found that states with a PMP
had a lower quarterly increase in both of these measures,
although only the intentional exposures reported to poi-
son centers measure was statistically significant (an in-
crease of 1.91% per quarter in states with no PMP that
quarter versus an increase of only 0.2% in states with
a PMP, p = 0.036). These findings differ with results by
Paulozzi and colleagues [50], who found that PMP pres-
ence in a state did not predict opioid overdose mortality.
What is the relationship between opioids analgesic abuse
and heroin abuse? Will efforts to reduce the supply of
opioid analgesics lead to an unintended increase in
heroin use and potential opioid overdoses?
Unick GJ, et al. [51] Using national data from the Nation-
wide Inpatient Survey and the US Census, the authors an-
alyzed hospitals’ annual rates of heroin overdose and
prescription opioid overdose. They found than an increase
in a hospital’s prescription opioid overdose rate predicted
Gordon et al. Addiction Science & Clinical Practice 2013, 8:18 Page 8 of 13
http://www.ascpjournal.org/content/8/1/18subsequent increase in heroin overdose rate, and the re-
verse was also true. They concluded that use and conse-
quences of these two types of opioids are “intertwined.”
Data from the National Survey on Drug Use and Health
raise further concern about an increase in heroin use in re-
cent years [52]. Together, these findings may portend
greater problems with heroin in the future as national ef-
forts to reduce prescription opioid misuse are implemented
and are a call for vigilance and preventative measures.
Cicero TJ, et al. [53] Cicero and colleagues analyzed
oxycodone and heroin use among patients entering
treatment for opioid dependence quarterly from July
2009 through March 2012 to identify changes before
and after release of the abuse-deterrent formulation of
long acting oxycodone in August 2010. They found a de-
crease in the percent of patients using long-acting
hydrocodone and an increase in the percent of patients
using heroin associated with the new formulation. These
findings highlight the importance of considering that re-
moval of one source of opioids is likely to increase an-
other potentially more dangerous one.
Implications for practice
Generalists are likely to face increasing inquiries from pa-
tients seeking guidance about or prescriptions for legal-
ized, medical marijuana, and it is important to keep
abreast of emerging science. Recent studies in this review
indicate that light marijuana use is unlikely to have ad-
verse effects on pulmonary function, but patients should
be cautioned against driving or operating heavy machinery
after marijuana use. Although it appears that light alcohol
use may reduce cardiovascular risk, the amount of reduc-
tion is not known, and patients may be at risk of develop-
ing certain cancers even with light use. Therefore, at this
time, generalists should not encourage light alcohol intake.
The recent increases in opioid analgesic misuse and over-
dose are very concerning, and generalists should take pre-
cautions when prescribing opioids. Clinicians and public
health officials should be aware that efforts to reduce the
supply of prescription opioids could have a negative con-
sequence of increasing heroin use.
Use of pharmacotherapy for addiction treatment in
primary care
Currently, pharmacotherapies are available to treat alcohol,
opioid, and nicotine dependence. Although several other
medications are currently under investigation, the three ap-
proved medications available to treat alcohol use disorders
include disulfiram, an aldehyde dehydrogenase inhibitor;
naltrexone, an opioid antagonist which modulates dopa-
mine in the nucleus accumbens; and acamprosate, a GABA
agonist/glutamate antagonist. Available pharmacotherapies
for opioid use disorders include methadone, a full opioid
agonist; buprenorphine, a partial opioid agonist at the muopioid receptor; and naltrexone, an opioid antagonist. Fi-
nally, various nicotine replacement therapies, buproprion (a
dopamine reuptake inhibitor originally marketed as an anti-
depressant) and varenicline (a partial nicotine agonist) are
available pharmacotherapeutic agents for smoking cessa-
tion. Several recent studies have addressed important clin-
ical questions regarding the use of pharmacotherapy for
addiction treatment in primary care.
Are certain subpopulations of alcohol-dependent patients
more likely to respond to naltrexone pharmacotherapy?
Fucito L, et al. [54] Nearly half of alcohol-dependent pa-
tients also smoke cigarettes [55], and nicotine dependence
is associated with a greater urge to drink, increased risk of
relapse after treatment, and heavier drinking upon relapse
[56]. Naltrexone is an effective treatment for alcohol de-
pendence [57,58]. This secondary data analysis of the
Combined Pharmacotherapies and Behavioral Interven-
tions for Alcohol Dependence (COMBINE) study [59]
assessed whether smoking moderated naltrexone’s effect
on drinking in alcohol-dependent patients and whether
naltrexone had any effect on smoking among alcohol-
dependent patients. Of the 1383 patients enrolled in the
study, 55% smoked cigarettes, and cigarette smoking was
associated with poorer treatment retention and outcomes.
Among smokers, those receiving naltrexone had a higher
percentage of days abstinent from alcohol (mean = 78 days
[+/− SE 0.97] versus mean =72 days [+/− SE 1.8], p =
0.004), and lower number of drinking consequences
(mean = 13.6 [+/− SE 1.04] versus mean = 17.5 [+/− SE
1.1], p = 0.01) as measured by the 50-item Drinker Inven-
tory of Consequences Questionnaire. Nonsmokers re-
ported a similar percentage of days abstinent (mean = 74.0
days [+/− SE 2.0] versus 74.6 days [+/− SE 1.8], p = 0.8)
and drinking consequences (mean 9.7[ +/− SE 0.9] versus
9.5 [+/− 0.8], p = 0.9) regardless of treatment assignment.
Smoking is prevalent among patients with alcohol de-
pendence and is a predictor of poor treatment retention
and outcomes [56]. However, alcohol-dependent smokers
receiving naltrexone do benefit from naltrexone with im-
proved alcohol use outcomes [58].
Is varenicline associated with serious adverse
cardiovascular events?
Prochaska J, et al. [60] Varenicline has been found to be
an effective agent for smoking cessation and for sustaining
abstinence [61]; yet, in a recent study, the rate of cardio-
vascular serious adverse events was 7% in the varenicline
group and 5.7% in the placebo group [62]. This systematic
review and meta-analysis investigated the rate of serious
treatment-emergent cardiovascular adverse events (de-
fined as occurring during treatment or within 30 days of
discontinuation) in all published randomized controlled
trials of varenicline for tobacco cessation [60]. Twenty-
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with active cardiovascular disease, and 11 included pa-
tients with a history of cardiovascular disease. The authors
explored four different summary measures to assess car-
diovascular risk: the Mantel-Haenszel versions of the risk
difference, relative risk, odds ratio, and the Petos odds ra-
tio. A summary estimate for risk was also calculated by
comparing the four summary statistics at the trial level by
grouping the studies by presence versus absence of events
and equal versus unequal numbers of events, and then or-
dering the groups by increasing evidence of a varenicline
effect. Rates of treatment-emergent serious cardiovascular
adverse events were 0.63% (34 of 5431) in the varenicline
groups and 0.47% (18 of 3801) in the placebo groups.
Based on the four different summary measures, vareni-
cline treatment was not associated with increases in the
risk of serious cardiovascular adverse events. The sum-
mary estimate for risk difference was 0.27% (95% CI, 0.10-
0.63, p = 0.15), which was neither statistically, nor likely,
clinically significant.
Paying attention to bias and differences in study design,
the authors of this systematic review and meta-analysis—
which included all published trials to date—found no
increase in serious treatment-emergent cardiovascular
adverse events associated with varenicline use for tobacco
cessation. Most trials included patients with current or
past cardiovascular disease, and more than one-third of
studies did not observe a single serious adverse event.
Do combined pharmacotherapy and behavioral
interventions have efficacy for smoking cessation?
Stead L, et al. [63] Combination pharmacotherapy and be-
havioral counseling is often recommended in addiction
treatment, but the effect size of combined treatment is not
known. This systematic review included 41 randomized or
quasi-randomized studies evaluating combination treatment
approaches for smoking cessation among more than 20,000
participants. One large study, which implemented an inten-
sive intervention that included multiple group sessions,
long-term maintenance, recycling contacts, and extended
availability of nicotine gum, contributed substantially to
study heterogeneity [64]. Of the 40 studies not focusing on
such an intensive intervention, evidence suggested a benefit
of combination pharmacotherapy (often including nicotine
replacement therapy) and behavioral treatment (RR = 1.82
[95% CI, 1.66-2.0]) with moderate statistical heterogeneity
(12-40%). Interventions combining pharmacotherapy and
behavioral support improved smoking cessation outcomes
compared with minimal intervention.
Is implantable naltrexone efficacious for treating
polysubstance abuse?
Tiihonen J, et al. [65] Long-acting naltrexone reduces opi-
oid use in patients with opioid dependence and alcoholuse in patients with alcohol dependence, but polydrug use
is common, and there is no effective pharmacotherapy for
polydrug dependence. The objective of this investigation
was to examine the effectiveness of implantable naltrex-
one in patients with concurrent heroin and amphet-
amine dependence. This was a trial of 100 outpatients
in St. Petersburg, Russia with both heroin and amphet-
amine dependence who were randomized to receive a
1000 mg naltrexone implant versus placebo for 10
weeks, analyzed via an intent-to-treat approach. Study
retention was 52% for patients receiving naltrexone versus
28% for patients receiving placebo (p= 0.01). Thirty-eight
percent of patients in the naltrexone group (n = 19) had
drug-free urine samples compared with 16% (n = 8) in the
placebo group (p = 0.01), with 52% versus 20% having
opioid-free urine tests (p< 0.001) and 40% versus 24% hav-
ing amphetamine-free urine tests (p = 0.09). Despite sig-
nificant study discontinuation, this study confirms that
patients with concurrent opioid and amphetamine de-
pendence receiving long-acting naltrexone have improved
treatment retention and decreased heroin use compared
with patients receiving placebo. Although long-acting nal-
trexone may be effective for decreasing amphetamine use
in this population, further study is warranted.
Implications for practice
Safe and effective pharmacotherapies exist for alcohol, opi-
oid, and nicotine dependence. However, the recent litera-
ture has addressed important questions regarding the use
of these pharmacotherapies in clinical care. Naltrexone is
known to be an effective treatment for reducing heavy
drinking in alcohol-dependent patients, and this effect has
been demonstrated in patients who also smoke. The safety
of varenicline for tobacco use has been questioned;
however, it is not associated with treatment-emergent
cardiovascular adverse events in patients with or with-
out pre-existing cardiovascular disease. Additionally,
nicotine dependence responds better to combination
pharmacotherapy and brief behavioral counseling over
either modality alone. Finally, investigation into a single
pharmacotherapeutic agent, namely implantable nal-
trexone, to treat coexisting heroin and amphetamine
dependence confirmed the efficacy of this agent to treat
opioid dependence but did not show efficacy for am-
phetamine use outcomes.
Integration of addiction treatment and medical care
The Institute of Medicine has called for collaboration and
coordination among care providers for patients with com-
binations of medical, mental health, and substance use dis-
orders [66]. Integration of medical, mental health, and
addiction treatment has potential benefits for patients,
such as the creation of a “one-stop shop” requiring fewer
visits to fewer places for patients and fostering longitudinal
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standing and trust [67]. For providers, integrated care facil-
itates daily direct communication and collaboration that
results in a team of providers sharing the burden of caring
for complicated patients. Several recent studies addressed
important clinical questions for the integration of addiction
treatment and medical care.
Does improved quality of chronic disease management
among primary care patients with addiction result in
improved addiction outcomes?
Kim TW, et al. [68] Health-care reform encourages addic-
tion treatment to shift from acute care delivery that is sep-
arate from the rest of health care to a chronic disease
model more integrated within health homes that can man-
age patients with multiple overlapping problems [69]. It is
not clear how quality of chronic disease management
(CDM) relates to addiction treatment outcomes.
This secondary analysis of data from a primary care-
based CDM randomized clinical trial for patients with ad-
dictions determined the association of 1) engagement in
care and 2) CDM quality with addiction severity and ab-
stinence at follow-up. The primary-care–based CDM team
in this intervention included a nurse, social worker, intern-
ist, and psychiatrist, all of whom were experienced in the
care of patients with substance use disorders. Engagement
in care was defined as at least two visits to the CDM clinic
team within 30 days of initiating care. Quality of CDM
was measured by the Patient Assessment of Chronic Ill-
ness Care (PACIC) survey for both CDM clinical care,
specifically, and for their overall addiction care. The
PACIC is a 20-item instrument where higher scores indi-
cate care consistent with the chronic care model. Engage-
ment in the CDM was not associated with abstinence or
addiction severity. Higher self-reported quality of CDM
clinical care was associated with lower drug use severity.
Higher self-reported quality of overall addiction care was
associated with increased odds of abstinence and lower al-
cohol severity. Perceived quality of CDM care was associ-
ated with better addiction outcomes regardless of the
source of the CDM care, whereas a visit-based, frequency
measure of care engagement was not.
Can buprenorphine/naloxone be used for patients with
pain and addiction?
Fox AD, et al. [70], Pade PA, et al. [71] Pain is common
among patient with opioid dependence [72]. Buprenor-
phine is a partial opioid agonist FDA-approved in sublin-
gual tablet and film form for the treatment of opioid
dependence (combined with naloxone to deter intraven-
ous use), and in transdermal and injectable forms as an
analgesic. Due to the ceiling effect of buprenorphine’s opi-
oid activity, opioid-dependent patients with chronic pain
may not be good candidates for buprenorphine, andguidelines recommend methadone for these patients. Fur-
thermore, primary care providers may be ill-equipped to
treat these patients without help from pain or addiction
specialists.
Two studies addressed the issue of using buprenor-
phine/naloxone among chronic pain patients with opioid
dependence. First, a prospective cohort study of 82 pa-
tients initiating buprenorphine/naloxone for opioid de-
pendence investigated whether chronic pain was associated
with retention in care or opioid use at six months [70].
Using the Brief Pain Inventory instrument, 60% of patients
reported chronic pain at baseline, and 38% reported persist-
ent pain at follow-up. No significant difference in retention
or opioid use was detected at follow-up for patients with
pain at baseline or persistent pain at follow-up. For those
with pain at baseline, mean pain scores decreased from 7.3
to 6.0 at six months.
Second, a retrospective chart review of 143 veterans
with opioid dependence and chronic pain, who were
treated with buprenorphine through a primary-care–based
co-occurring disorders clinic, investigated treatment re-
tention and pain scores [71]. Only 11% reported heroin as
their primary opioid of abuse; the remainder had prescrip-
tion opioid dependence at baseline. The median daily
morphine milligram (mg) equivalent use was 120 mg at
baseline. After stabilization on buprenorphine/naloxone,
the median daily dose was 16 mg/4 mg. At six months,
65% of patients were retained on buprenorphine/nalox-
one, and 5% tapered off all opioids. Pain scores improved
from 6.4 to 5.6.
Contrary to guidelines advising caution when prescrib-
ing buprenorphine to opioid-dependent patients with
chronic pain, emerging literature suggests that buprenor-
phine is effective for improving both addiction and pain in
patients suffering from both conditions. This is encour-
aging news for primary care providers considering transi-
tioning patients who develop opioid analgesic use disorder
in the course of managing their chronic pain onto bupre-
norphine. Opioid-dependent patients with chronic pain
treated with buprenorphine/naloxone receive similar ben-
efits as those without chronic pain. Favorable addiction
and pain outcomes can be achieved in patients with opioid
dependence stabilized on buprenorphine/naloxone. For
the primary care provider treating a patient with bupre-
norphine for opioid use dependence, this study provides
preliminary evidence that pain syndromes can be subse-
quently treated with buprenorphine.
How best to deliver hepatitis C treatment to people who
use drugs?
Dimova RB, et al. [73], Martinez AD, et al. [74], and Stein
MR, et al. [75] Patients with either active or prior sub-
stance use are often excluded from hepatitis C treatment
clinical trials and receive hepatitis C treatment at lower
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tematic review and meta-analysis of hepatitis C treatment
trials that included current and former drug users [73]
sought to determine factors associated with treatment
completion and sustained viral response. Researchers in-
cluded 36 studies of 2866 patients who used drugs.
Treatment completion among trial participants who used
drugs was 83% and sustained viral response was 55%,
which are rates similar to what has been found in subjects
of other clinical trials. Incorporation of addiction treatment
and social support services into the care plan was associ-
ated with higher treatment completion. Using a multidis-
ciplinary team to deliver care was associated with higher
sustained viral response to treatment rates.
Two case series of innovative hepatitis C treatment
models among methadone maintenance patients, which
were recently published and not included in this meta-
analysis, reinforce these findings. First, Martinez and col-
leagues [74] describe an integrated multidisciplinary team
in their retrospective record review of 401 patients receiv-
ing methadone maintenance treatment who were provided
hepatitis C management. The team included an internist,
addiction medicine physician, and hepatology expert. Over
two years, among 24 patients who initiated treatment,
79% completed treatment and 54% achieved a sustained
viral response.
Second, Stein and colleagues [75] describe concurrent
group hepatitis C treatment among 42 methadone main-
tenance patients. In concurrent group treatment, groups
of patients initiated treatment at the same time and
attended weekly provider and peer-led group sessions that
included review of side effects, discussion of treatment ad-
herence, administration of interferon injections, a brief
physical exam, and a meditation exercise. In this series,
the sustained viral response was 42% in a group of patients
who had genotype 1, which was similar to clinical trial
rates for this genotype and the treatment they received.
Together, the meta-analysis and case series demonstrate
that HCV treatment for people who use drugs is feasible
and facilitated by integration with addiction treatment.
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